Sony has listed The Legend of Zelda and Resident Evil among its upcoming theatrical releases, according to its Q3 FY25 financial report. The documents outline the company’s film calendar from late 2026 onward, confirming Resident Evil for September 18, 2026, and The Legend of Zelda for May 7, 2027. Both titles are labeled under Columbia Pictures as part of Sony’s broader release slate.
Resident Evil is scheduled as one of 10 films planned for 2026. The cast includes Austin Abrams, Paul Walter Hauser, Zach Cherry, Kali Reis, and Johnno Wilson. The release date places the film in the fall 2026 window, positioning it within Sony’s active theatrical lineup for that year.
The Legend of Zelda is among eight films scheduled for release starting in January 2027, with a confirmed release date of May 7, 2027. Its placement in the lineup indicates a significant spring release for Columbia Pictures. Although specific production details were not provided in the financial summary, the inclusion of this title in the official slate highlights Sony’s dedication to bringing the franchise to theaters.
The Q3 FY25 financial results provide context for these announcements. Sony’s Pictures segment reported sales of 353.3 billion yen, equivalent to 2,295 million dollars, with operating income of 30.9 billion yen, or 197 million dollars. Adjusted OIBDA reached 286 million dollars. Within the revenue breakdown for the quarter, streaming services generated 337 million dollars, television productions accounted for 718 million dollars, and motion pictures’ theatrical revenue totaled 98 million dollars, down from 244 million dollars in the same quarter of the previous fiscal year.
Sony’s overall slate includes 18 films scheduled through 2028, featuring established franchises such as Spider-Man Brand New Day in July 2026, Jumanji 3 in December 2026, Spider-Man Beyond the Spider-Verse in June 2027, and a Beatles cinematic event in April 2028. The addition of Resident Evil and The Legend of Zelda reflects the company’s continued reliance on recognizable intellectual properties as part of its long-term theatrical strategy.
